1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Orna Therapeutics Acquires ReNAgade

M&A Deal Summary

Orna Therapeutics Acquires ReNAgade

On May 23, 2024, Orna Therapeutics acquired life science company ReNAgade

Acquisition Highlights
  • This is Orna Therapeutics’ 1st transaction in the Life Science sector.
  • This is Orna Therapeutics’ 1st transaction in the United States.
  • This is Orna Therapeutics’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2024-05-23
Target ReNAgade
Sector Life Science
Buyer(s) Orna Therapeutics
Deal Type Add-on Acquisition

Target

ReNAgade

Cambridge, Massachusetts, United States
ReNAgade combines RNA delivery platforms with RNA platforms allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines. ReNAgade was formed in 2021 and is based in Cambridge, Massachusetts.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Orna Therapeutics

Watertown, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA). The company's proprietary platform combines novel technology to design circular RNA transcripts that drive protein expression with validated and unique delivery solutions. Orna Therapeutics is based in Watertown, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal